

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number  
**WO 2005/098023 A1**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/18**, G01N 21/64, C12Q 1/04, C12M 1/34

(21) International Application Number: PCT/CA2005/000312

(22) International Filing Date: 2 March 2005 (02.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/561,766 12 April 2004 (12.04.2004) US

(71) Applicant (for all designated States except US): **UNIVERSITY TECHNOLOGIES INTERNATIONAL INC.** [CA/CA]; 3553-31 Street NW, Suite 130, Calgary, Alberta T2L 2K7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STOREY, Douglas** [CA/CA]; 9 Silverstone Mews, NW, Calgary, Alberta T3B 5K8 (CA). **FIELD, Tyler** [CA/IE]; School of Pharmacy, Queens University of Belfast, 97 Lisburn Rd., Belfast, BT9 7BR (IE). **RAMAGE, Gordon** [CA/GB]; Department of Biological and Biomedical Sciences., Glasgow Caledonian University., Cowcaddens Road, Glasgow, Scotland G4 0BA (GB).

(74) Agents: **MITCHELL, Richard, J.** et al.; c/o Marks & Clerk, P.O. Box 957, Station B., Ottawa, Ontario K1P 5S7 (CA).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **MICROBIAL GROWTH ASSAY**



(57) Abstract: Susceptibility of sessile microorganisms to antimicrobial agents is tested with a method comprising growing the microorganisms on a support to form a biofilm, contacting the biofilm with a metabolic substrate having a chromogenic and/or fluorogenic moiety to continue a base-line metabolic activity of the biofilm, contacting the biofilm with one or more antimicrobial agents, determining an experimental metabolic activity of the biofilm by measuring a signal from the metabolic substrate, and comparing the base-line metabolic activity with the experimental activity. The biofilm may be grown in a device comprising a plurality of wells, each well having a planar bottom and at least one wall, a plurality of supports comprising discs for growing the biofilm, each support disposed within a well perpendicular to the planar bottom, and at least one cover that fittably seals the top of each well.

WO 2005/098023 A1



*HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *with international search report*